[Influenza and pneumococcal vaccination in adults]

Area of Science:

• Immunology
• Public Health
• Epidemiology

Context:

• Seasonal influenza and invasive pneumococcal infections lead to significant morbidity and mortality, especially in vulnerable populations like the elderly and those with comorbidities.
• Current vaccination coverage in Germany for influenza (60% in >60 years) and pneumococcal disease (20% in target groups) falls short of recommended targets (WHO 75%).
• Immunosenescence, the age-related decline in immune function, necessitates improved vaccine immunogenicity.

Purpose:

• To highlight the public health burden of seasonal influenza and invasive pneumococcal disease in Germany.
• To underscore the inadequacy of current vaccination rates and the need for improved vaccine strategies.
• To advocate for enhanced immunogenicity through novel vaccine approaches and increased physician emphasis on vaccination.

Summary:

• Intradermal vaccination demonstrates potential for higher antibody levels compared to traditional methods, addressing immunosenescence.
• The pneumococcal polysaccharide vaccine is effective, preventing 60-80% of invasive infections and reducing mortality, yet uptake remains low.
• Physician recommendation and patient education are critical to improve vaccination coverage for both influenza and pneumococcal disease.

Impact:

• Improved vaccine strategies, such as intradermal application, could enhance protection against influenza, particularly in aging populations.
• Increased pneumococcal vaccination rates could significantly reduce the annual burden of invasive pneumococcal infections and associated deaths in Germany.
• A concerted effort involving healthcare providers and public health initiatives is essential to achieve optimal vaccination coverage and mitigate the impact of these preventable diseases.